{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:38:54Z","timestamp":1761748734199,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.acvd.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T08:09:54Z","timestamp":1636445394000},"page":"814-817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial"],"prefix":"10.1016","volume":"114","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter Brunner-La","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2021.10.003_bib0085","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2021.10.003_bib0090","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2021.10.003_bib0095","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(20)31964-4","article-title":"Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis","volume":"396","author":"Narula","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2021.10.003_bib0100","first-page":"27","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","author":"Diaz","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.acvd.2021.10.003_bib0105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11906-008-0076-0","article-title":"Pharmacologic modulation of ACE2 expression","volume":"10","author":"Soler","year":"2008","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.acvd.2021.10.003_bib0110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.acvd.2021.10.003_bib0115","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"Sama","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.003_bib0120","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.003_bib0125","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of COVID-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2021.10.003_bib0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.acvd.2021.10.003_bib0135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs. continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2021.10.003_bib0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.acvd.2021.10.003_bib0145","doi-asserted-by":"crossref","first-page":"110112","DOI":"10.1016\/j.mehy.2020.110112","article-title":"Spironolactone may provide protection from SARS-CoV-2: targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)","volume":"143","author":"Cadegiani","year":"2020","journal-title":"Med Hypotheses"},{"journal-title":"Eur J Heart Fail","year":"2020","author":"Pellicori","key":"10.1016\/j.acvd.2021.10.003_bib0150"},{"key":"10.1016\/j.acvd.2021.10.003_bib0155","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart OMics in AGEing (HOMAGE) randomized clinical trial","author":"Cleland","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2021.10.003_bib0160","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1093\/eurheartj\/ehaa697","article-title":"Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation","volume":"41","author":"Wallentin","year":"2020","journal-title":"Eur Heart J"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213621001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:47:56Z","timestamp":1761745676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213621001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1875213621001728"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2021.10.003","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}